Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. more
Time Frame | HAE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -5.48% | -2.06% | -0.55% |
1-Month Return | -10.66% | -1.92% | 2.72% |
3-Month Return | 4.18% | -10.4% | 7.66% |
6-Month Return | -7.76% | -4.6% | 10.15% |
1-Year Return | -10.86% | 4.06% | 27.53% |
3-Year Return | 57.54% | 1.94% | 32.31% |
5-Year Return | -34% | 36.48% | 89.2% |
10-Year Return | 106.37% | 97.46% | 194.59% |
Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 988.48M | 870.46M | 993.20M | 1.17B | 1.31B | [{"date":"2020-03-31","value":75.51,"profit":true},{"date":"2021-03-31","value":66.5,"profit":true},{"date":"2022-03-31","value":75.87,"profit":true},{"date":"2023-03-31","value":89.28,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Cost of Revenue | 503.97M | 472.63M | 487.69M | 553.56M | 617.51M | [{"date":"2020-03-31","value":81.61,"profit":true},{"date":"2021-03-31","value":76.54,"profit":true},{"date":"2022-03-31","value":78.98,"profit":true},{"date":"2023-03-31","value":89.64,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Gross Profit | 484.51M | 397.84M | 505.50M | 615.10M | 691.55M | [{"date":"2020-03-31","value":70.06,"profit":true},{"date":"2021-03-31","value":57.53,"profit":true},{"date":"2022-03-31","value":73.1,"profit":true},{"date":"2023-03-31","value":88.94,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Gross Margin | 49.02% | 45.70% | 50.90% | 52.63% | 52.83% | [{"date":"2020-03-31","value":92.78,"profit":true},{"date":"2021-03-31","value":86.52,"profit":true},{"date":"2022-03-31","value":96.34,"profit":true},{"date":"2023-03-31","value":99.63,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Expenses | 330.56M | 339.88M | 433.78M | 459.06M | 526.66M | [{"date":"2020-03-31","value":62.77,"profit":true},{"date":"2021-03-31","value":64.53,"profit":true},{"date":"2022-03-31","value":82.36,"profit":true},{"date":"2023-03-31","value":87.16,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Operating Income | 153.95M | 57.96M | 80.75M | 156.03M | 164.88M | [{"date":"2020-03-31","value":93.37,"profit":true},{"date":"2021-03-31","value":35.15,"profit":true},{"date":"2022-03-31","value":48.97,"profit":true},{"date":"2023-03-31","value":94.63,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Total Non-Operating Income/Expense | (83.00M) | (1.88M) | (34.24M) | (29.26M) | (26.04M) | [{"date":"2020-03-31","value":-8299700000,"profit":false},{"date":"2021-03-31","value":-188400000,"profit":false},{"date":"2022-03-31","value":-3424200000,"profit":false},{"date":"2023-03-31","value":-2926000000,"profit":false},{"date":"2024-03-31","value":-2603600000,"profit":false}] |
Pre-Tax Income | 87.15M | 72.91M | 63.63M | 141.40M | 151.87M | [{"date":"2020-03-31","value":57.39,"profit":true},{"date":"2021-03-31","value":48.01,"profit":true},{"date":"2022-03-31","value":41.9,"profit":true},{"date":"2023-03-31","value":93.11,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Income Taxes | 10.63M | (6.56M) | 20.25M | 26.00M | 34.31M | [{"date":"2020-03-31","value":30.97,"profit":true},{"date":"2021-03-31","value":-19.11,"profit":false},{"date":"2022-03-31","value":59.04,"profit":true},{"date":"2023-03-31","value":75.79,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Income After Taxes | 76.53M | 79.47M | 43.38M | 115.40M | 117.56M | [{"date":"2020-03-31","value":65.1,"profit":true},{"date":"2021-03-31","value":67.6,"profit":true},{"date":"2022-03-31","value":36.9,"profit":true},{"date":"2023-03-31","value":98.17,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Income From Continuous Operations | 76.53M | 79.47M | 43.38M | 115.40M | 117.56M | [{"date":"2020-03-31","value":65.1,"profit":true},{"date":"2021-03-31","value":67.6,"profit":true},{"date":"2022-03-31","value":36.9,"profit":true},{"date":"2023-03-31","value":98.17,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2020-03-31","value":"-","profit":true},{"date":"2021-03-31","value":"-","profit":true},{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true}] |
Net Income | 76.53M | 79.47M | 43.38M | 115.40M | 117.56M | [{"date":"2020-03-31","value":65.1,"profit":true},{"date":"2021-03-31","value":67.6,"profit":true},{"date":"2022-03-31","value":36.9,"profit":true},{"date":"2023-03-31","value":98.17,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
EPS (Diluted) | 3.31 | 2.35 | 2.59 | 3.03 | 3.98 | [{"date":"2020-03-31","value":83.17,"profit":true},{"date":"2021-03-31","value":59.05,"profit":true},{"date":"2022-03-31","value":65.08,"profit":true},{"date":"2023-03-31","value":76.13,"profit":true},{"date":"2024-03-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
HAE | |
---|---|
Cash Ratio | 1.09 |
Current Ratio | 3.49 |
Quick Ratio | 2.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
HAE | |
---|---|
ROA (LTM) | 5.88% |
ROE (LTM) | 13.97% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
HAE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.65 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
HAE | |
---|---|
Trailing PE | 32.68 |
Forward PE | 15.92 |
P/S (TTM) | 2.91 |
P/B | 4.69 |
Price/FCF | 100 |
EV/R | 3.71 |
EV/Ebitda | 18.23 |
PEG | 1.33 |
Haemonetics Corporation (HAE) share price today is $78.77
Yes, Indians can buy shares of Haemonetics Corporation (HAE) on Vested. To buy Haemonetics Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HAE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Haemonetics Corporation (HAE) via the Vested app. You can start investing in Haemonetics Corporation (HAE) with a minimum investment of $1.
You can invest in shares of Haemonetics Corporation (HAE) via Vested in three simple steps:
The 52-week high price of Haemonetics Corporation (HAE) is $97.97. The 52-week low price of Haemonetics Corporation (HAE) is $70.25.
The price-to-earnings (P/E) ratio of Haemonetics Corporation (HAE) is 34.0539
The price-to-book (P/B) ratio of Haemonetics Corporation (HAE) is 4.69
The dividend yield of Haemonetics Corporation (HAE) is 0.00%
The market capitalization of Haemonetics Corporation (HAE) is $4.12B
The stock symbol (or ticker) of Haemonetics Corporation is HAE